ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3104

Early Proteinuria Response in Real Life Situation Predicts Long-Term Lupus Renal Outcome in Ethnically Diverse Group with Biopsy-Proven Nephritis

Michelle Lopes1, Luciana Seguro1, Maite Castro2, Danielle Daffre3, Eduardo Ferreira Borba2 and Eloisa Bonfa4, 1Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, 3São Paulo University, São Paulo, Brazil, 4Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Lupus nephritis, outcomes and proteinuria

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV: Biomarkers

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Treat to target strategies are becoming the best approach for several rheumatic disorders. Recently retrospective analyses of two important lupus trials have reported that proteinuria is the single best predictor of renal outcome in lupus patients. Samples from these trials were however mainly Caucasians and mostly from patients in the first nephritis episode with non-severe renal involvement at entry. In addition, on average, adherence to intervention protocols is higher in clinical trials than in non-research settings. The purpose of this study was therefore to determine in real-life situation if proteinuria was also a good predictor of renal outcome in a geographical region with more racial diversity.

Methods: 94 biopsy-proven lupus nephritis patients with at least 7 years longitudinal follow-up at the Rheumatology Division of a tertiary university hospital were consecutively selected. Data were obtained using a standardized electronic database protocol including demographic data, clinical and laboratorial findings and treatment. Proteinuria, serum creatinine (SCr), urine red blood casts (RBC) and anti-dsDNA antibody were evaluated at baseline and after 3, 6, 12 months and then 7 years of follow-up. We assessed the ability of these biomarkers at these different time points to predict good long term renal outcome (defined as SCr<1.5mg/dl) at 7 years. Receiver operating characteristic (ROC) curves were generated to assess parameter cutoff and performance at these time points and to select the best parameter considering sensitivity, specificity, positive and negative predictive values. Kaplan Meier curves were used to assess renal survival of each group.

Results: 80 (85.1%) were women, 38 (40.4%) were non-white patients and 38 (40%) were not in the first episode of nephritis. At baseline, patients had mean SCr of 1.73±1.34 mg/dl, proteinuria 5.46±4.51g/24h, albumin 2.45±0.78g/dl and SLEDAI 9.46±4.23. Proteinuria <0.83g/24h at 12 months of follow-up was the best single predictor of good long-term renal outcome (Sensitivity=90.3%, Specificity=78.3%, PPV=62.0% e NPV=90.3% AUC=0.86, p<0.001). The addition of other variables to proteinuria analysis such as SCr and RBC at month 12 did not improve the predictive performance of this parameter. Further evaluation of the proposed proteinuria cut-off (<0.83g/24h at 12 months) revealed that this parameter is a good predictor of 7 years renal survival (defined as years free of dialysis) for pure membranous (p=0.005), proliferative nephritis (p=0.043), blacks (p=0.002), whites (p=0.001), anti-dsDNA positive (p=0.001), males (p=0.028) and females (p=0.003) patients.

Conclusion: We demonstrated in a real-life situation that proteinuria at 12 months of follow-up was the single best predictor of good renal outcome at 7 years for an ethnically diverse group. We further validated this parameter as long-term predictor of renal outcome for distinct histological classes, races, gender and anti-dsDNA profile.


Disclosure: M. Lopes, None; L. Seguro, None; M. Castro, None; D. Daffre, None; E. F. Borba, None; E. Bonfa, None.

To cite this abstract in AMA style:

Lopes M, Seguro L, Castro M, Daffre D, Borba EF, Bonfa E. Early Proteinuria Response in Real Life Situation Predicts Long-Term Lupus Renal Outcome in Ethnically Diverse Group with Biopsy-Proven Nephritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/early-proteinuria-response-in-real-life-situation-predicts-long-term-lupus-renal-outcome-in-ethnically-diverse-group-with-biopsy-proven-nephritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-proteinuria-response-in-real-life-situation-predicts-long-term-lupus-renal-outcome-in-ethnically-diverse-group-with-biopsy-proven-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology